GAO, FDA identify tactics to fight economic adulteration

Manufacturer reluctance to share information about adulterated ingredients hinders the FDA from preventing this form of drug degradation, the agency told the U.S. Government Accountability Office. In addition, the regulator said segregating economic from other forms of adulteration--a distinction currently not made--would help it fight the practice. The GAO finds that the FDA needs better coordination of its many efforts to fight the scourge. GAO report (PDF)

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.